Cantargia: Fast Track in IL1-RAP High Patients - Redeye
The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strategy of developing nadunolimab in patients high IL1RAP expression levels. Redeye provides a brief comment.
ANNONS
The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strategy of developing nadunolimab in patients high IL1RAP expression levels. Redeye provides a brief comment.
